| Withdrawn | Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Can NCT03091842 | University of Southern California | N/A |
| Completed | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis NCT03691493 | Emory University | Phase 2 |
| Recruiting | S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative NCT03723928 | SWOG Cancer Research Network | N/A |
| Withdrawn | Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Can NCT03666819 | Mayo Clinic | Phase 2 |
| Withdrawn | Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HE NCT03377101 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors NCT03523195 | Fred Hutchinson Cancer Center | N/A |
| Active Not Recruiting | Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Can NCT03359954 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Me NCT03070002 | Northwestern University | Phase 2 |
| Withdrawn | Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer NCT03042897 | University of Southern California | N/A |
| Terminated | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage NCT03128619 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative NCT03132467 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrin NCT02398773 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative NCT02648477 | City of Hope Medical Center | Phase 2 |
| Completed | Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Earl NCT02526498 | Rutgers, The State University of New Jersey | Phase 2 |
| Terminated | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Bre NCT02457910 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Completed | Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic NCT02219789 | Mayo Clinic | Phase 1 |
| Completed | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients NCT02152943 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery NCT01754519 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck C NCT01846091 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Brea NCT01750073 | University of Nebraska | Phase 2 |
| Terminated | MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer NCT01319539 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer NCT01275677 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer NCT01281163 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or NCT00785291 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cance NCT00390455 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Re NCT00118157 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive NCT00338728 | M.D. Anderson Cancer Center | Phase 2 |